Find the products and resources you are looking for!
Miltenyi Biotec distribution:
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
AML is a condition where the bone marrow makes large numbers of immature white blood cell known as myeloid cells. Myeloid leukemia occurs when these white cells multiply uncontrollably in the marrow, crowding out other normal cells and leading to impaired function of the blood building system.
The sudden rate at which the leukemic cells replace the normal blood and bone marrow cells is the parameter that qualifies the form of the disease as acute. Eventually the regular production of blood cells is destroyed and the risk of infection or bleeding increases significantly.
Treatment of AML is usually divided into two phases:
The elimination of leukemic cells is usually accomplished using chemotherapy. This can be achieved with multiple drugs during a planned sequence of treatments.
The intensity of the treatment depends on several factors, including:
If induction therapy is successful, no detectable leukemic cells will remain following this phase of treatment. This state is called a complete remission.
However, induction therapy often does not destroy all of the leukemic cells, leaving a small number to persist. In some cases, often dependent on disease stage or chromosomal abnormalities, the cancer will return within several years. The recurrence of cancer is called relapse.
Once the AML patient is in complete remission, further treatment will be given to kill any remaining leukemic cells and prevent relapse.
For intermediate or high-risk AML, consolidation therapy options include chemotherapy with or without stem cell transplantation. The choice and intensity of treatment is dependent on the same factors described in the induction therapy section above.
Authorized by U.S. Federal Law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this use has not been demonstrated.
Indications for Use
The CliniMACS® CD34 Reagent System is indicated for processing hematopoietic progenitor cells collected by apheresis (HPC, Apheresis) from an allogeneic, HLA-identical, sibling donor to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional graft versus host disease (GVHD) prophylaxis in patients with acute myeloid leukemia (AML) in first morphologic complete remission.
Do not use CD34+ cells prepared with CliniMACS CD34 Reagent System in patients with known hypersensitivity to murine (mouse) proteins or iron dextran.
Copyright © 2020 Miltenyi Biotec and/or its affiliates. All rights reserved.